Telomerase in cancer diagnosis and therapy: a clinical perspective.

Telomerase in cancer diagnosis and therapy: a clinical perspective. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Telomerase in cancer diagnosis and therapy: a clinical perspective. Abstract Text:

A M Burger,

Curing cancers is one of the most challenging tasks of modern medicine. The major problem is the heterogeneity of human tumours and thus finding a 'universal' target for cancer treatment. The discovery that the expression of the enzyme telomerase is a hallmark of immortality and cancer, and that it is found in the majority (>85%) of human tumours but is repressed in most normal cells, has therefore caused considerable excitement. These observations led to the design of potential telomerase inhibitors and ideas about targeting telomerase in the clinic. To date, several classes of telomerase inhibitory agents have been identified and are in preclinical development. However, the approach has not yet been tested clinically. Because of the proposed function of telomerase, and the understanding that replicative cell senescence or cell death result from progressive telomere shortening during successive cell divisions, even complete enzyme inhibition will not produce immediate cell death. Designing clinical trials for promising telomerase inhibitors requires consideration of the novel mechanism of action of these drugs. A lag period between initiation of treatment and occurrence of effects is likely, and thus anti-telomerase therapy might best be given in adjuvant treatment protocols after initial tumour debulking therapy and in combination with other cytostatic agents. The available knowledge of telomerase biology and its association with human tumours suggests that telomerase inhibition might prove a valuable addition to current cancer treatment regimens.

Telomerase in cancer diagnosis and therapy: a clinical perspective. Publishing Authors By Initials

AM Burger,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Telomerase in cancer diagnosis and therapy: a clinical perspective. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: BioDrugs : clinical immunotherapeutics, biopharmac

VOLUME: 12

Page Numbers: 413-22

Journal Abbreviation:

ISSN: 1173-8804

DAY: 22

MONTH: Dec

YEAR: 1999

Telomerase in cancer diagnosis and therapy: a clinical perspective. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9705305

Telomerase in cancer diagnosis and therapy: a clinical perspective. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Telomerase in cancer diagnosis and therapy: a clinical perspective. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Telomerase in cancer diagnosis and therapy: a clinical perspective.

AFFILIATION: Tumor Biology Center, University of Freiburg, Freiburg, Germany.

Country: New Zealand

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: BioDrugs

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Telomerase in cancer diagnosis and therapy: a clinical perspective Related Publications

• A framework and methods for incorporating gender-related issues in wildlife risk assessment: gender-related differences in metal levels and other contaminants as a case study.
• A model for selecting bioindicators to monitor radionuclide concentrations using Amchitka Island in the Aleutians as a case study.
• Assessment and management of risk to wildlife from cadmium.
• Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients.
• Cancer stem cells and individualized therapy.
• Continuous-wave broadly tunable Cr(2+):ZnSe laser.
• Editorial comment on: Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study.
• Genomic and nongenomic effects of estrogen signaling in human endometrial cells: involvement of the growth factor receptor signaling downstream AKT pathway.
• Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
• Mixed effects modeling of weight change associated with placebo and pregabalin administration.
• Molecular analysis of xenograft models of human cancer cachexia--possibilities for therapeutic intervention.
• Monoclonal antibodies to guinea pig interferon-gamma: Tools for cytokine detection and neutralization.
• Not Available
• Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia.
• Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.
• Product update.
• Protective sustainability of ecosystems using Department of Energy buffer lands as a case study.
• Quantitative thin-layer chromatography of cobalamin complexes.
• Telomerase and its potential for therapeutic intervention.
• Telomerase in cancer diagnosis and therapy: a clinical perspective.
• The assessment of alexithymia in medical settings: implications for understanding and treating health problems.
• The effect on ecological systems of remediation to protect human health.
• Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
• Therapeutic implications of leukemic stem cell pathways.
• Treatment seeking for alcohol and drug use disorders by immigrants to the Netherlands: retrospective, population-based, cohort study.
• [Endothelioma as variety of tubular mesothelioma of the ovary.]
• [Horner's syndrome after fracture of the first rib]
• [New knowledge and experience with the urinary organs in pregnancy.]
• [Not Available.]
• [ON TRANSVERSE PRESENTATION.]